HeraMED continues to forge value adding partnerships
The good news keeps flowing for medical technology company, HeraMED Limited (ASX:HMD) with the company announcing today that it has entered into an agreement with leading midwife service provider, Kinderheldin GmbH.
This follows news earlier in the week that the company had received FDA clearance for its HeraBEAT foetal heart monitoring device, which built on other promising collaboration agreements with leading healthcare group’s such as Mayo Clinic.
HeraMED is revolutionising the pregnancy experience by empowering personalised, continuous and proactive home monitoring, delivering better care at a lower cost.
Central to developing the group’s new technologies is the development of an extensive database that will provide a bank of information in relation to pregnancy histories as detailed by hospitals and other medical tuitions.
Provision of web-based online midwife services
Under the agreement announced today, HeraMED and Kinderheldin will collaborate to provide Kinderheldin’s web-based online midwife service to expecting mothers using the company’s HeraBEAT smart foetal heart rate monitor.
This will culminate in the inaugural release of HeraBEAT Plus and progresses HeraMED’s ongoing push into telemedicine ahead of the US launch in 2020.
Kinderheldin (www.kinderheldin.de) is a leading midwife service provider based in Berlin.
The group has developed a web based, online platform that offers expecting parents access to large number of midwives through online chat services or telephones.
Kinderheldin’s team of midwives is supported by an experienced medical advisory board which includes top-tier physicians and an in-country software development team.
HeraMED and German distributor Duttenhofer will offer the online service to consumers using the HeraBEAT device via individual access codes, which will be provided when the device has been purchased.
Kinderheldin’s midwives will also be able to access data generated from HeraBEAT, which will assist them in making more informed decisions and providing a better duty of care.
Bringing insurance companies on board
Kinderheldin and HeraMED are also progressing discussions with insurance companies in the Kinderheldin network for use of the device and service.
Kinderheldin works with approximately fifty insurance companies including some of Germany’s oldest and largest.
Its partners include Barmer, BKK Mobil Oil and HEK amongst others.
The group also has co-operation agreements with five major hospitals in the country, and both parties will progress discussions with these hospitals to deploy HeraMED’s solutions.
All parties are working to progress the launch of the solution in time for Duttenhofer’s planned launch of HeraBEAT in Germany, Austria and Switzerland.
Highlighting the competitive advantages that this agreement provides, HeraMED chief executive and co-founder David Groberman said, “This agreement provides HeraMED with a significant differentiator and competitive advantage.
‘’Having a midwifery service that expecting mothers and new parents can access as part of our service offering puts the company leagues ahead as it pushes further into telehealth and connected care.
“Kinderheldin is a tremendous partner for HeraMED as it boasts strong relationships with some of Germany’s oldest and largest insurance companies and hospital groups.
“We look forward to progressing discussions with the top-tier organisations in their network with the aim to implement HeraBEAT and potentially HeraCARE more broadly.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.